The proteome of clear cell ovarian carcinoma

Jennifer X. Ji; Dawn R. Cochrane; Gian Luca Negri; Shane Colborne; Sandra E. Spencer Miko; Lynn N. Hoang; David Farnell; Basile Tessier-Cloutier; Jutta Huvila; Emily Thompson; Samuel Leung; Derek Chiu; Christine Chow; Monica Ta; Martin Köbel; Lucas Feil; Michael Anglesio; Ellen L. Goode; Kelly Bolton; Gregg B. Morin; David G. Huntsman

doi:10.1002/path.6006

The proteome of clear cell ovarian carcinoma

Jennifer X. Ji, Dawn R. Cochrane, Gian Luca Negri, Shane Colborne, Sandra E. Spencer Miko, Lynn N. Hoang, David Farnell, Basile Tessier-Cloutier, Jutta Huvila, Emily Thompson, Samuel Leung, Derek Chiu, Christine Chow, Monica Ta, Martin Köbel, Lucas Feil, Michael Anglesio, Ellen L. Goode, Kelly Bolton, Gregg B. MorinDavid G. Huntsman

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

Clear cell ovarian carcinoma (CCOC) is the second most common subtype of epithelial ovarian carcinoma. Late-stage CCOC is not responsive to gold-standard chemotherapy and results in suboptimal outcomes for patients. In-depth molecular insight is urgently needed to stratify the disease and drive therapeutic development. We conducted global proteomics for 192 cases of CCOC and compared these with other epithelial ovarian carcinoma subtypes. Our results showed distinct proteomic differences in CCOC compared with other epithelial ovarian cancer subtypes including alterations in lipid and purine metabolism pathways. Furthermore, we report potential clinically significant proteomic subgroups within CCOC, suggesting the biologic plausibility of stratified treatment for this cancer. Taken together, our results provide a comprehensive understanding of the CCOC proteomic landscape to facilitate future understanding and research of this disease.

Original language	English
Pages (from-to)	325-338
Number of pages	14
Journal	Journal of Pathology
Volume	258
Issue number	4
DOIs	https://doi.org/10.1002/path.6006
State	Published - Dec 2022

Keywords

clear cell ovarian carcinoma
endometrioid ovarian carcinoma
epithelial ovarian carcinoma
high-grade serous ovarian carcinoma
immunohistochemistry
proteomics

Access to Document

10.1002/path.6006

Cite this

Ji, J. X., Cochrane, D. R., Negri, G. L., Colborne, S., Spencer Miko, S. E., Hoang, L. N., Farnell, D., Tessier-Cloutier, B., Huvila, J., Thompson, E., Leung, S., Chiu, D., Chow, C., Ta, M., Köbel, M., Feil, L., Anglesio, M., Goode, E. L., Bolton, K., ... Huntsman, D. G. (2022). The proteome of clear cell ovarian carcinoma. Journal of Pathology, 258(4), 325-338. https://doi.org/10.1002/path.6006

@article{42dec2fe4ee347a1863a214a1f6ce7a0,

title = "The proteome of clear cell ovarian carcinoma",

abstract = "Clear cell ovarian carcinoma (CCOC) is the second most common subtype of epithelial ovarian carcinoma. Late-stage CCOC is not responsive to gold-standard chemotherapy and results in suboptimal outcomes for patients. In-depth molecular insight is urgently needed to stratify the disease and drive therapeutic development. We conducted global proteomics for 192 cases of CCOC and compared these with other epithelial ovarian carcinoma subtypes. Our results showed distinct proteomic differences in CCOC compared with other epithelial ovarian cancer subtypes including alterations in lipid and purine metabolism pathways. Furthermore, we report potential clinically significant proteomic subgroups within CCOC, suggesting the biologic plausibility of stratified treatment for this cancer. Taken together, our results provide a comprehensive understanding of the CCOC proteomic landscape to facilitate future understanding and research of this disease.",

keywords = "clear cell ovarian carcinoma, endometrioid ovarian carcinoma, epithelial ovarian carcinoma, high-grade serous ovarian carcinoma, immunohistochemistry, proteomics",

author = "Ji, {Jennifer X.} and Cochrane, {Dawn R.} and Negri, {Gian Luca} and Shane Colborne and {Spencer Miko}, {Sandra E.} and Hoang, {Lynn N.} and David Farnell and Basile Tessier-Cloutier and Jutta Huvila and Emily Thompson and Samuel Leung and Derek Chiu and Christine Chow and Monica Ta and Martin K{\"o}bel and Lucas Feil and Michael Anglesio and Goode, {Ellen L.} and Kelly Bolton and Morin, {Gregg B.} and Huntsman, {David G.}",

note = "Publisher Copyright: {\textcopyright} 2022 The Pathological Society of Great Britain and Ireland.",

year = "2022",

month = dec,

doi = "10.1002/path.6006",

language = "English",

volume = "258",

pages = "325--338",

journal = "Journal of Pathology",

issn = "0022-3417",

number = "4",

}

Ji, JX, Cochrane, DR, Negri, GL, Colborne, S, Spencer Miko, SE, Hoang, LN, Farnell, D, Tessier-Cloutier, B, Huvila, J, Thompson, E, Leung, S, Chiu, D, Chow, C, Ta, M, Köbel, M, Feil, L, Anglesio, M, Goode, EL, Bolton, K, Morin, GB & Huntsman, DG 2022, 'The proteome of clear cell ovarian carcinoma', Journal of Pathology, vol. 258, no. 4, pp. 325-338. https://doi.org/10.1002/path.6006

TY - JOUR

T1 - The proteome of clear cell ovarian carcinoma

AU - Ji, Jennifer X.

AU - Cochrane, Dawn R.

AU - Negri, Gian Luca

AU - Colborne, Shane

AU - Spencer Miko, Sandra E.

AU - Hoang, Lynn N.

AU - Farnell, David

AU - Tessier-Cloutier, Basile

AU - Huvila, Jutta

AU - Thompson, Emily

AU - Leung, Samuel

AU - Chiu, Derek

AU - Chow, Christine

AU - Ta, Monica

AU - Köbel, Martin

AU - Feil, Lucas

AU - Anglesio, Michael

AU - Goode, Ellen L.

AU - Bolton, Kelly

AU - Morin, Gregg B.

AU - Huntsman, David G.

PY - 2022/12

Y1 - 2022/12

N2 - Clear cell ovarian carcinoma (CCOC) is the second most common subtype of epithelial ovarian carcinoma. Late-stage CCOC is not responsive to gold-standard chemotherapy and results in suboptimal outcomes for patients. In-depth molecular insight is urgently needed to stratify the disease and drive therapeutic development. We conducted global proteomics for 192 cases of CCOC and compared these with other epithelial ovarian carcinoma subtypes. Our results showed distinct proteomic differences in CCOC compared with other epithelial ovarian cancer subtypes including alterations in lipid and purine metabolism pathways. Furthermore, we report potential clinically significant proteomic subgroups within CCOC, suggesting the biologic plausibility of stratified treatment for this cancer. Taken together, our results provide a comprehensive understanding of the CCOC proteomic landscape to facilitate future understanding and research of this disease.

AB - Clear cell ovarian carcinoma (CCOC) is the second most common subtype of epithelial ovarian carcinoma. Late-stage CCOC is not responsive to gold-standard chemotherapy and results in suboptimal outcomes for patients. In-depth molecular insight is urgently needed to stratify the disease and drive therapeutic development. We conducted global proteomics for 192 cases of CCOC and compared these with other epithelial ovarian carcinoma subtypes. Our results showed distinct proteomic differences in CCOC compared with other epithelial ovarian cancer subtypes including alterations in lipid and purine metabolism pathways. Furthermore, we report potential clinically significant proteomic subgroups within CCOC, suggesting the biologic plausibility of stratified treatment for this cancer. Taken together, our results provide a comprehensive understanding of the CCOC proteomic landscape to facilitate future understanding and research of this disease.

KW - clear cell ovarian carcinoma

KW - endometrioid ovarian carcinoma

KW - epithelial ovarian carcinoma

KW - high-grade serous ovarian carcinoma

KW - immunohistochemistry

KW - proteomics

UR - http://www.scopus.com/inward/record.url?scp=85141108965&partnerID=8YFLogxK

U2 - 10.1002/path.6006

DO - 10.1002/path.6006

M3 - Article

C2 - 36031730

AN - SCOPUS:85141108965

SN - 0022-3417

VL - 258

SP - 325

EP - 338

JO - Journal of Pathology

JF - Journal of Pathology

IS - 4

ER -

The proteome of clear cell ovarian carcinoma

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this